Sparks commentary

Healthcare

Sparks

Isofol (ST: ISOFOL) commences Phase Ib/II arfolitixorin trial
Published by Arron Aatkar, PhD

Isofol has announced that the first patient has been included in the Phase Ib/II trial of arfolitixorin in metastatic colorectal cancer. The trial has been designed to assess the drug candidate as part of the standard 5-FU-based first-line therapy for the condition. The trial is being conducted in two stages. The initial Phase Ib part will evaluate the risk/benefit profile of escalating doses in a new dosing regimen. The second part of the trial will compare the highest dose from Phase Ib with one of the lower doses, with efficacy parameters as primary endpoints.

Latest

Healthcare | Comment

Herantis Pharma (HEL: HRTIS) – a step closer to Phase II

Investment Companies | Comment

The Biotech Growth Trust (BIOG) reported encouraging H126 results

TMT | Comment

Nanoco (LSE:NANO) settles LG litigation for $5m

Healthcare | Comment

Mendus (OMX: IMMU) announces c SEK50m directed share issue